Note: Descriptions are shown in the official language in which they were submitted.
- 2113916
1 72222-216
6-CHLORO-5-FLUORO-3-(2-THENOYL)-2-OXINDOLE-
l-CARBOXAMIDE AS AN ANALGESIC AND
ANTIINFLAMMATORY AGENT
Thls lnventlon relates to a pharmaceutlcal compositlon
for treating an lnflammatory dlsease ln a human sub~ect wlthout
lnduclng protelnurla.
Backqround of the Inventlon
Kadln ln Unlted States Patent 4,556,672 descrlbes cer-
taln 2-oxlndole-1-carboxamlde compounds wlth acyl substltuents at
the 3-posltlon whlch are lnhlbltors of cyclo-oxygenase (CO) and
llpoxygenase (LO) enzymes. These compounds are useful as anal-
geslc agents ln mammals and are useful ln amelloratlng or elimlna-
tlng paln, such as paln experlenced by patlents recoverlng from
surgery or trauma. These compounds are also useful for chronic
admlnistratlon to mammals to allevlate the symptoms of chronlc
diseases such as the inflammatlon and paln assoclated wlth rheuma-
told arthrltls and osteoarthrltls. Kadln speclflcally clalms a
method of ellcltlng an analgeslc response, and also a method of
treatlng an lnflammatory dlsease, ln a mammalian sub~ect, whlch
comprlses treatlng sald mammallan sub~ect wlth an effectlve amount
of member selected from a genus of 2-oxlndole-1-carboxamldes.
Thls genus lncludes the chemlcal compound 6-chloro-5-fluoro-3-(2-
thenoyl)-2-oxlndole-1-carboxamlde. However, use of this latter
compound is not speclfically identlfled. The 2-oxlndole-1-
carboxamldes of Kadln are hlghly effectlve analgeslcs and antl-
lnflammatorles; but 5-chloro-3-(2-thenoyl)-2-oxlndole-1-carboxa-
mlde ln thls group of compounds has been found to lnduce non-
'~C
`- 2113916
2 72222-216
progressive, reversible proteinuria in some patients. 6-Chloro-5-
fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide does not induce
proteinuria.
Summary of the Invention
This invention provides a pharmaceutical composition for
ellclting an analgeslc or antlinflammatory response in a human
sub~ect while maintaining a normal urine protein/creatinine ratio
in the sub~ect. The pharmaceutical composition comprises, in
admixture with a pharmaceutically acceptable carrler, an analgeslc
or antllnflammatory, and non-proteinurlc ellcltlng amount of 6-
chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide or a
pharmaceutically acceptable base salt thereof. The invention also
provides 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide
or a pharmaceutically acceptable base salt thereof for eliclting
an analgesic or antiinflammatory response in a human sub~ect while
maintaining a normal urine protein/creatinlne ratio.
Detailed DescriPtion of the Inventlon
6-Chloro-5-fluoro-3-(2-thenoyl)-2-oxlndole-1-carboxamide
(l) is prepared by the following sequence of reactlons as describ-
ed in U.S. 4,556,672 and preparations 1-3.
F ¦ F
\~ +ClCH2COCl--\~ NHC-~H2Cl
II III
2113916
2a 72222-216
AlC13 ~ ~\HN~ O
IV
1 ) ClS02NCO ~ ~
2 ) Water Cl l O
CONH~
- 2113916
-3-
F CJ~S~J
[~COCI
C I N 0
CONH2
I
6-Chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide is acidic and forms
base salts. All such base salts are within the scope of this invention and they can be
prepared by conventional methods. For example, they can be prepared simply by
combining the acidic and basic entities, usually in a stoichiometric ratio, in either an
aqueous, non-aqueous or partially aqueous medium, as appropriate, or by
interconverting one salt with another salt. The salts are recovered either by filtration,
by precipitation with another solvent followed by filtration, by evaporation of the solvent,
as appropriate, or, in the case of aqueous solutions, by Iyophilization. Preferred salts
are those of esters of naturally occurring amino acids.
6-Chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide is recognized to exist
in a number of enolic forms, all such tautomers are within the scope of this invention.
"Significant increase or decrease" for proteinuria effects is herein defined as an
increase or decrease having statistical significance as determined by conducting an
analysis of variance (ANOVA). First, a regression line is fitted to protein/creatinine (PC)
ratio data for each patient and treatment period, and a slope is determined. The slope
is then analyzed using an ANOVA to test for sequence, period and treatment effects,
to determine if a difference exists between the control and treated groups.
6-Chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide and salts thereof
possess analgesic activity. This activity can be demonstrated in mice by showing
blockage of the abdominal stretching induced by administration of 2-phenyl-1,4-
benzoquinone (PBQ). The method is based on that of Siegmund et al., Proc. Soc. Exp.
2113gl6
-4-
Biol. Med., 95, 729-731, (1957), as adapted for high throughput [see further Milne and
Twomey, Aqents and Actions, 10, 31 -37, (1980)] . The mice used in these experiments
are Carworth males, albino CF-1 strain, weighing 18-20 g. All mice are fasted overnight
prior to drug administration and testing.
6-Chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide is dissolved or
suspended in a vehicle consisting of ethanol (5%), emulphor 620 (a mixture of
polyoxyethylene fatty acid esters, 5%) and saline (90%). This vehicle also served as
control. Doses are on a logarithmic scale (i.e.,..Ø32, 1.0, 3.2, 10.32...mg/kg), and are
calculated from weights of the salt when applicable. The route of administration is oral,
with concentrations varied to allow a constant dosage of 10 ml/kg of mouse. The
aforesaid method of Milne and Towney is used to determine efficacy and potency.
Mice are treated with compounds orally, and one hour later received PBQ, 2 mg/kgintraperitoneally. Individual mice are then immediately placed in a warmed lucite
chamber, and, starting five minutes after PBQ administration, the number of abdominal
constrictions during the subsequent 5 minutes are recorded. The degree of analgesic
protection, Maximal Possible Effect (%MPE), is calculated on the basis of suppression
of abdominal constriction relative to counts from concurrent control animals run on the
same day. At least four such determinations provide dose-response data for generation
of an MPE50, the best estimate of the dose that reduces abdominal constriction to 50%
of control levels.
6-Chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide also possesses anti-
inflammatory activity. This activity can be demonstrated in rats by a method based on
the standard carrageenin-induced rat-foot edema test. ~Winter et al., Proc. Soc. Exp.
Biol. Med., 111, 544, (1963~].
Unanesthetized, adult, male, albino rats of 150 g to 190 g body weight are
numbered, weighed, and an ink mark placed on the right lateral malleolus. Each paw
is immersed in mercury exactly to the ink mark. The mercury is contained in a glass
cylinder, connected to a Statham Pressure Transducer. The output from the transducer
is fed through a control unit to a microvoltameter. The volume of mercury displaced
by the immersed paw is read. The drug is given by gavage. One hour after drug
administration, edema is induced by injection of 0.05 ml of 1 % solution of carrageenin
into the plantar tissue of the marked paws. Immediately thereafter, the volume of the
2113916
-5-
injected foot is measured. The increase in foot volume 3 hours after the injection of
carrageenin constitutes the individual inflammatory response.
The analgesic activity of 6-chioro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-
carboxamide and salts thereof make them useful for acute administration to mammals
5 for the control of pain, e.g., post-operative pain and the pain of trauma. Additionally
6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide is useful for chronic
administration to mammals for the alleviation of the symptoms of chronic diseases,
such as the inflammation of rheumatoid arthritis, and the pain associated with
inflammation in osteoarthritis and other musculoskeletal and inflammatory disorders.
Large amounts of creatinine and much smaller amounts of protein are normally
excreted in the urine of normal human subjects, and a protein/creatinine ratio of
approximately 0.05 to 0.1 is usually maintained. A normal urine protein/creatinine ratio
is herein defined as the protein/creatinine ratio exhibited by the subject prior to
administration of any medication. A "non-proteinuria eliciting amount" is herein defined
15 as a dosage of an analgesic or antiinflammatory compound which does not significantly
increase the urine protein/creatinine ratio of the subject over the normal value.
5-Chloro-3-(2-thenoyl)-2-oxindole-1-carboxamide has been found to cause
proteinuria in 10-15% of patients within four weeks at 80 mg/day; the proteinurea is
non-progressive and reversible upon discontinuation of medication. The compound of
20 this invention does not cause proteinuria at 320 mg/day. See Examples 1 and 2.
When 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide or a
pharmaceutically acceptable salt thereof is to be used as either an analgesic agent or
an anti-inflammatory agent, it can be administered to a human subject either alone, or,
preferably, in combination with pharmaceutically-acceptable carriers or diluents in a
25 pharmaceutical composition, according to standard pharmaceutical practice. The
compound can be administered orally or parenterally. Parenteral administration
includes intravenous, intramuscular, intraperitoneal, subcutaneous and topical
administration .
In a pharmaceutical composition comprising 6-chloro-5-fluoro-3-(2-thenoyl)-2-
30 oxindole-1 -carboxamide, or a pharmaceutically-acceptable salt thereof, the weight ratio
of carrier to active ingredient will normally be in the range from 1:4 to 4:1, and
preferably 1 :2 to 2:1 . However, in any given case, the ratio chosen will depend on such
211391~
6 72222-216
factors as the solublllty of the active component, the dosage
contemplated and the preclse route of admlnlstratlon.
For oral use of 6-chloro-5-fluoro-3-(2-thenoyl)-2-
oxlndole-l-carboxamlde, the compound can be admlnlstered, for
example, ln the form of tablets or capsules, or as an aqueous
solutlon or suspenslon. In the case of tablets for oral use,
carrlers whlch are commonly used lnclude lactose and corn starch,
and lubrlcatlng agents, such as magneslum stearate, are commonly
added. For oral administratlon in capsule form, useful dlluents
are lactose and drled corn starch. When aqueous suspensions are
requlred for oral use, the actlve lngredlent ls comblned wlth
emulslfylng and suspendlng agents. If deslred, certaln sweetenlng
and/or flavorlng agents can be added. For lntramuscular, lntra-
perltoneal, subcutaneous and lntravenous use, sterlle solutlons of
the actlve lngredlent are usually prepared, and the pH of the
solutlons should be sultably ad~usted and buffered. For lntra-
venous use, the total concentratlon of solutes should be control-
led to render the preparatlon lsotonlc.
When 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxlndole-1-
carboxamlde or salt thereof ls used ln a human sub~ect, the dallydosage wlll normally be determlned by the prescribing physlclan.
Moreover, the dosage wlll vary according to the age, weight and
response of the lndividual patient, as well as the severity of the
patlent's symptoms and the potency of the partlcular formulation
belng administered. However, for acute administration to relieve
pain, an effective dose in most instances will be 0.01 to 0.5 g as
needed (e.g., every four to six hours). For chronic admlnlstra-
- 2113916
6a 72222-216
tion, ln most lnstances an effectlve dose wlll be from 0.01 to 1.0
g per day, and preferably 1 to 320 mg per day and more preferably
40 to 160 mg per day, in slngle or divided doses. On the other
hand, it may be necessary to use dosages outslde these limits in
some cases.
The pharmaceutical composition in practical use is nor-
mally contained in a commercial package. The package usually
carries lnstructions or indications that the pharmaceutical compo-
sition can be used as an analgesic or antiinflammatory agent while
maintalnlng a normal urine protein/creatinine ratio.
The followlng examples and preparations are being
provided solely for the purpose of further illustration.
2113916
EXAMPLE 1
Using adouble blind placebo-controlled design,6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide was administered to 36 patients at dose levels of 40, 80, 160
and 320 mg, once daily. A single dose was given on day 1, followed by a seven day
5 washout period, and then dosing was continued for a further 21 days. At each dose
level, ninesubjects received 6-chloro-5-fluoro-3-(thenoyl)-2-oxindole-1 -carboxamide and
three subjects received placebo, with the placebo given as an identical matching form.
The study was double blind with respect to within group assignment and single blind
with respect to between group assignment. Computer generated randomization was
10 used to assign subjects to the various treatment regimens. Each dose (drug and
placebo) was administered after an overnight fast with 240 ml of water. On the first and
last day of dosing, blood sufficient for 1 ml plasma was collected at hour 0 (for
baseline) and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, 120, 144 and 168 hours
postdose (for the last day of dosing 192, 216 and 240 hour samples were also
15 collected). Urine (24 hr) was also collected on the first and last day of dosing for the
determination of creatinine, uric acid, ~32-microglobulin, albumin and total protein. In
addition, following the 2nd, 8th and 22nd dose, and 240 hours after the last dose, one
20 ml aliquot of urine, following the first am void but prior to the administration of study
medication, was withdrawn for measurement of quantitative protein and creatinine.
20 Throughout these studies, there were no significant differences in the urine
protein/creatinine ratios between the drug treated groups and the placebo treated
groups.
EXAMPLE 2
Using a double blind, placebo controlled, crossover design,6-chloro-5-fluoro-3-
25 (2-thenoyl)-2-oxindole-1-carboxamide was administered to 25 patients at a dose level
of 80 mg/day. Patients were randomized to receive either 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide for four weeks followed by placebo for four weeks,
or to receive placebo for four weeks followed by 6-chloro-5-fluoro-3-(2-thenoyl)-2-
oxindole-1-carboxamide for four weeks. Patients could switch to the second leg of the
30 treatment regimen earlier if symptoms became intolerable. Before starting treatment
all existing non-steroidal antiinflammatory medication was stopped and a washoutperiod of one week implemented. Urine protein/creatinine ratio was determined atbaseline and weekly during the study. The protocol required 24 hour urine collections
2113916
to confirm any increase in estimated 24 hour protein excretion based on the
protein/creatinine ratios. No significant changes in the urine protein/creatinine ratio was
observed during 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide
treatment and no significant differences between the protein/creatinine ratio during 6-
5 chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide and placebo treatment were
seen.
PREPARATION 1
6-Chloro-5-fluoro-2-oxindole
10To 130 ml of toluene was added, with stirring, 24.0 g (0.165 mole) of 3-chloro-4-
fluoroaniline and 13.5 ml (0.166 mole) of pyridine. The resulting solution was cooled
to ca. 0C and 13.2 ml (0.166 mole) of 2-chloroacetyl chloride was added. The
reaction mixture was stirred at room temperature for 5 hours and then it was extracted
twice with 100 ml of 1N hydrochloric acid, followed by 100 ml of saturated sodium
15 chloride solution. The resulting toluene solution was dried using magnesium sulfate,
and then it was concentrated in vacuo to give 32.6 9 (88% yield) of N-(2-chloroacteyl)-3-
chloro-4-fluoroaniline.
A 26.63 9 sample of the N-(2-chloroacetyl)-3-chloro-4-fluoroaniline was
thoroughly mixed with 64 g of anhydrous aluminum chloride, and the mixture was
20 heated at 210-230C for 8.5 hours. The reaction mixture was then poured onto a
mixture of ice and 1 N hydrochloric acid, with stirring. Stirring was continued for 30
minutes, and then the solid was collected by filtration (22.0 g). The solid was dissolved
in 1 :1 ethyl acetate-hexane and chromatographed on 800 9 of silica gel. Elution of the
column, followed by evaporation of the fractions, produced 11.7 g of the N-(2-
25 chloroacetyl)-3-chloro-4-fluoroaniline, followed by 3.0 9 of 6-chloro-5-fluoro-2-oxindole.
The latter material was recrystallized from toluene to give 1.70 g (7% yield) of the title
compound, m.p. 196-206C. Analysis by NMR spectroscopy indicated that the
product was contaminated by some 4-chloro-5-fluoro-2-oxindole.
30PREPARATION 2
6-Chloro-5-fluoro-2-oxindole-1 -carboxamide
To a slurry of 6-chloro-5-fluoro-2-oxindole (0.04 mole) in acetonitrile (80 ml) was
added chlorosulfonyl isocyanate (6.65 9, 0.047 mole) and the mixture was stirred for
2113916
g
45 minutes. Water (100 ml) was then added and the aqueous mixture was stirred for
one hour. The precipitate which formed was filtered off and recrystallized from
acetonitrile to give 0.92 9 of the title product. Extraction of the filtrate from the aqueous
reaction mixture with ethyl acetate (300 ml) followed by drying the extract over MgSO4
5 and then evaporating it under reduced pressure gave additional product.
Recrystallization from acetonitrile gave an additional 2.2 9 of product, m.p. 229-231 C.
PREPARATION 3
6-Chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1 -carboxamide
A stirred slurry of 0.1 mole of 6-chloro-5-fluoro-oxindole-2-carboxamide and 26.9
9 (0.22 mole) of 4-(N,N-dimethylamino)pyridine in 200 ml of N,N-dimethylformamide was
cooled to ice-bath temperature, and then a solution of 16.1 9 (0.11 mole) of 2-thenoyl
chloride in 50 ml of N,N-dimethylformamide was added dropwise. Stirring was
continued for ca. 30 minutes and then the reaction mixture was poured into a mixture
15 of 1 liter of water and 75 ml of 3N hydrochloric acid. The resulting mixture was cooled
in an ice-bath, and then the solid was collected by filtration. The solid was washed with
water and then recrystallized from 1800 ml of acetic acid, to give 26.6 9 of the title
compound as fluffy, yellow crystals, m.p. 220-221 C.
